Israel-India partnership advances new osteoarthritis treatment

Israel-India partnership advances new osteoarthritis treatment

India’s Sun Pharma and Israel’s Moebius Medical published new data on MM-II, a non-opioid treatment for knee osteoarthritis. The studies, featured in the peer-reviewed Osteoarthritis and Cartilage journal, show that a single injection of MM-II can provide long-lasting pain relief and protect cartilage. The drug, developed in Israel and supported by Sun Pharma, recently received Fast Track Designation from the US FDA. New findings will be present…

Sun Pharma and Moebius Medical publish clinical and mechanistic data on non-opioid knee osteoarthritis treatment MM-II - Express Pharma

Sun Pharmaceutical Industries and Israel-based Moebius Medical have announced the publication of two peer-reviewed articles in Osteoarthritis and Cartilage, the official journal of the Osteoarthritis Research Society International (OARSI). The articles examine MM-II, a non-opioid product developed for the treatment of symptomatic knee osteoarthritis. MM-II consists of a proprietary suspension of large, empty, multilamellar liposomes. It is desig…